Cost Cuts And Digital Upgrades Will Strain Future Margins

Published
06 Apr 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$3.00
7.0% overvalued intrinsic discount
08 Aug
US$3.21
Loading
1Y
2.6%
7D
-0.3%

Author's Valuation

US$3.0

7.0% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 Aug 25
Fair value Decreased 10%

Consensus revenue growth forecasts for PetMed Express have deteriorated further into negative territory, driving a lower analyst price target from $3.35 to $3.00. What's in the News PetMed Express received a notice from Nasdaq for not timely filing its annual report, with a deadline to submit a compliance plan and potentially regain compliance by late December.

Shared on01 May 25